Home › Open-Angle Glaucoma › NCT06066645

Travoprost Intraocular Implant + iStent Infinite

Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite in Subjects With Open-angle Glaucoma or Ocular Hypertension

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* diagnosis of open-angle glaucoma or ocular hypertension
* qualifying IOP in the study eye

Exclusion Criteria:

* unmedicated (washed out) IOP of \>36 mmHg in the study eye
* hypersensitivity to travoprost or any other components of the travoprost intraocular implant
* vertical cup/disc ratio \> 0.8 in the study eye
* best spectacle corrected visual acuity of worse than 20/80 in either eye
* any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

About the study

Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and be followed for 12 months.

What is being tested

• Travoprost Intraocular Implant (drug)
• iStent infinite (device)
• Sham procedure (other)

Sponsor: Glaukos Corporation · Participants: 150 · Started: Sep 14, 2023

Contact the study team

• Study Director · Phone: 949-739-8749
• Study Manager · Phone: 949-739-8749

Official record on ClinicalTrials.gov — NCT06066645

Locations in the U.S.

Conditions

• Open-Angle Glaucoma

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.